Patents Examined by Marcela M. Cordero Garcia
  • Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptide
    Patent number: 10010578
    Abstract: Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 3, 2018
    Inventor: Claresa Levetan
  • Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
    Patent number: 10010577
    Abstract: Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 3, 2018
    Inventor: Claresa Levetan
  • Selective PYY compounds and uses thereof
    Patent number: 10005824
    Abstract: The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: June 26, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Carsten Jessen, Birgitte Schjellerup Wulff, Annika Sanfridson
  • Diagnostic kit for diagnosis of abnormal protein aggregation- or misfolding-related diseases using dissociation of protein aggregates
    Patent number: 10006920
    Abstract: The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of ?-amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: June 26, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Young Soo Kim, Dong Jin Kim, Hye Yun Kim, Soo Min Cho, Tae Song Kim, Hyunjin Kim, Sejin Lee, Kyoseon Hwang, Jee Hoon Roh, Jae-Young Koh
  • Peptides having effects on promoting wound healing, collagen production, angiogenesis, activation of immunocytes and applications thereof
    Patent number: 10005823
    Abstract: The present invention provides 11 peptides represented as SEQ ID NO: 1-11. The peptides have the ability of anti-virus and bacteria, and can reduce infections, clean necrotic tissue, and promote debridement so as to facilitate wound healing. Moreover, the peptides can also induce collagen secretion and activate fibroblasts and keratinocytes so as to stimulate angiogenesis. Thus, the peptides of the present invention are suitable for development as a health caring product to help an individual enhance recovery and immunity.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: June 26, 2018
    Assignee: TCI CO., LTD
    Inventors: Yung-Hsiang Lin, Chin-Hsiu Yu, Yun-Ching Tsai, Ciao-Ting Chen, Hsiang-Ling Su
  • Peptide pharmaceuticals
    Patent number: 10005817
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 26, 2018
    Assignee: EUMEDERIS PHARMACEUTICALS, INC.
    Inventor: John J. Nestor
  • Fluorescent imaging agents
    Patent number: 9999687
    Abstract: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 19, 2018
    Assignee: VisEn Medical, Inc.
    Inventors: Milind Rajopadhye, Kevin Groves, Dorin V. Preda
  • Nuclear targeting sequences
    Patent number: 10000771
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 19, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Dana Chuderland
  • Biodegradable microbead comprising anionic polymer for improving adsorptive power to anticancer drugs, and method for preparing same
    Patent number: 9999676
    Abstract: The present invention relates to a biodegradable microbead having improved adsorptive power to anticancer drugs, to a method for preparing same, and to a method for treating cancer using same. According to the present invention, a rigid bead having excellent adsorptive power to anticancer drugs can be prepared through cross-linking and an amide bond between an albumin and an anionic polymer. Also, the microbead of the present invention is prepared by a biocompatible and biodegradable polymer so as to be safe when applied to the human body. Further, the microbead of the present invention can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrients to a liver tumor, while continuously releasing anticancer drugs which are adsorbed into the surface of the bead. Thus, the present invention can be usefully applied to a chemoembolization of liver cancer.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 19, 2018
    Assignee: UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTER
    Inventors: Se Yoon Kim, Don Haeng Lee, Yixian Li
  • Glucose-regulating polypeptides and methods of making and using same
    Patent number: 10000543
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 19, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Method and composition for treatment of dyslipidemia and other diseases
    Patent number: 9987375
    Abstract: Anionic liposomes and apolipoprotein B-100 targeted immunoliposomes as therapeutic agents for dyslipidemia and related diseases, and compositions and methods for preparing same.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 5, 2018
    Inventors: Amirhossein Sahebkar, Ali Badiee, Mahmoud Reza Jaafari
  • Pegylated bioactive peptides and uses thereof
    Patent number: 9988428
    Abstract: Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: June 5, 2018
    Assignee: GRIFFON PHARMACEUTICALS INC.
    Inventor: Krishna G. Peri
  • Dipeptides as inhibitors of human immunoproteasomes
    Patent number: 9988421
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: June 5, 2018
    Assignee: Cornell University
    Inventors: Gang Lin, Carl Nathan, Aihao Ding, Xiaojing Ma
  • Compositions and methods for reducing ice crystal formation
    Patent number: 9986733
    Abstract: The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 5, 2018
    Assignee: X-Therma, Inc.
    Inventor: Xiaoxi Wei
  • Modified serpins for the treatment of bleeding disorders
    Patent number: 9982035
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 29, 2018
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Lantibiotic derivatives and process for their preparation
    Patent number: 9975930
    Abstract: The present invention concerns novel antibiotic compounds, which are lantibiotics, the processes for their preparation, their pharmaceutically acceptable salts, pharmaceutical compositions containing the lantibiotics, and their use as antibacterial agents. Compounds designated as lantibiotics, such as those of the present invention, are peptides belonging to the general class of antibiotic compounds, and are further generally characterized by the presence of the amino acids lanthionine and/or 3-methyllanthionine. The novel lantibiotic compounds are active against bacterial infections caused by Clostridium difficile, Staphylococcus spp., Streptococcus spp, Enterococcus spp., and other bacteria.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 22, 2018
    Assignee: NAICONS S.R.L.
    Inventors: Sonia I. Maffioli, Paolo Monciardini, Bruno Catacchio, Mariacristina Brunati, Carlo Mazzetti
  • Methods and uses of slit for treating fibrosis
    Patent number: 9974829
    Abstract: The present disclosure provides methods and uses of Slit protein and nucleic acid for inhibiting fibrosis and fibrotic-related disorders, for example, of the kidney, lung, heart, liver, or a wound. The Slit protein can be, for example, Slit2 or Slit2-N, or a Slit variant that can bind the Robo receptor and induce signalling. Also provided are pharmaceutical compositions comprising the Slit protein or nucleic acid and an additional anti-fibrotic agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 22, 2018
    Assignee: The Hospital for Sick Children
    Inventors: Lisa Annette Robinson, Darren Arthur Vee-Yip Yuen
  • Recombinant clostridial neurotoxins with increased duration of effect
    Patent number: 9975929
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: May 22, 2018
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt
  • Method of bone regeneration or bone augmentation
    Patent number: 9968660
    Abstract: The present invention provides a means effective for bone regeneration or bone augmentation. Provided is a method of bone regeneration or bone augmentation, comprising: implanting a porous composite at a site in need of the bone regeneration or bone augmentation, and administering parathyroid hormone (PTH) to a subject in need of the bone regeneration or bone augmentation, wherein the porous composite comprises calcium phosphate.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 15, 2018
    Assignee: TOYOBO CO., LTD.
    Inventors: Shinji Kamakura, Satoru Nakajou, Atsushi Iwai, Fumihiko Kajii, Hidenori Tanaka
  • Mass spectrometric assays for peptides
    Patent number: 9970943
    Abstract: Methods for interpretation of mass spectrometric tests for clinical biomarkers in which the amounts of internal standards are set to equal clinical evaluation thresholds, and preparations for adding stable isotope labeled peptide species to sample digests while minimizing losses and alterations in peptide stoichiometry.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: May 15, 2018
    Assignee: Anderson Forschung Group, LLC
    Inventor: N. Leigh Anderson